GlassScriptPhysician profile
Matthew L Offutt
NPI 1104867456
$5,507.93
in general payments reported to CMS, 2019-2025
32 companies · $613 in 2025
The $613 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $988 · 2020: $730 · 2021: $1,056 · 2022: $432 · 2023: $719 · 2024: $970 · 2025: $613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,281 · Education: $20.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,281.49 |
| Education | $20.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $860.10 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $752.41 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Astrazeneca Pharmaceuticals LP | $505.97 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $447.96 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $390.57 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $357.47 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $336.44 | 2019-2025 | Repatha, Otezla, Repatha |
| Merck Sharp & Dohme LLC | $306.58 | 2019-2025 | Gardasil 9, Capvaxive, Steglatro |
| Abbvie INC. | $276.34 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $172.17 | 2019-2023 | |
| Dynavax Technologies Corporation | $112.97 | 2024-2025 | Heplisav-B |
| Amarin Pharma, INC. | $111.89 | 2019-2021 | |
| Exact Sciences Corporation | $105.63 | 2024-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $98.24 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $89.67 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $81.35 | 2024-2025 | Voquezna |
| Abbott Laboratories | $78.23 | 2021-2024 | Freestyle Libre, Freestyle Libre 3 |
| Kowa Pharmaceuticals America, INC. | $68.68 | 2020-2021 | |
| Allergan, INC. | $65.89 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $45.20 | 2019-2020 | |
| Astellas Pharma US INC | $33.98 | 2024-2025 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.44 | 2024-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $27.51 | 2021 | |
| Siemens Medical Solutions USA, INC. | $26.45 | 2024 | Cios Spin |
| Biohaven Pharmaceutical Holding Company LTD. | $24.39 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $17.65 | 2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $15.81 | 2021 | |
| Insulet Corporation | $14.80 | 2025 | Omnipod |
| Shire North American Group INC | $13.70 | 2019 | |
| Esperion Therapeutics, INC. | $12.28 | 2020 | |
| Supernus Pharmaceuticals, INC. | $12.19 | 2019 | |
| Medtronic, INC. | $11.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Offutt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.